Author contributions
CRF
VIRUS, CRF
K.D.-J. is the principal investigator of the DiViD studies, including this intervention trial. He conceived the project, drafted the protocol, organized the staff and collaborations with partners, partnered with Apodemus/Curovir AB for the trial, organized the applications to the medicine agencies and ethics committees, organized the funding and the collaboration with INNODIA and related laboratories, planned and organized the statistical analysis and wrote the first and final drafts of this manuscript. L.K. managed the trial together with K.D.-J. and supervised the staff. He actively participated in writing the protocols, the applications to the medicines agencies, ethics committees and funding agencies, organized the collaboration with INNODIA database staff and the development of the INNODIA electronic CRF system. He participated in writing the SAP, analyzed the data and wrote all the drafts of the manuscript. I.M.M. was a PhD candidate and physician and performed all the study visits for the participants in Oslo, entered clinical data into the CRF system, collected and prepared all the samples together with T.R. and managed the biobank. She ensured the quality of the database, participated in writing the SAP, analyzed the data and wrote the manuscript. E.P. was a statistician. She participated in writing the SAP, analyzed the data and wrote the first and final drafts of the manuscript. F.B.M. and T.W.H. were PhD candidates and physicians and performed all the study visits in Copenhagen. They entered clinical data into the CRF system, and collected and prepared all the samples for storing and shipping. T.R. was a study nurse and performed all the study visits of participants in Oslo, entered clinical data into the CRF system and collected and prepared all the samples together with I.M.M. She organized the biobank and the shipping of samples to the international laboratories. J.W. was responsible for managing the GMP production of pleconaril and ribavirin at Anthem BioSciences in Bangalor and the GMP production of the investigational medicinal product at Unimedic in Matfors, Sweden. He also prepared the investigator’s brochure and investigational medicinal product dossier and arranged the logistics and distribution of the drugs with Birka BioStorages. N.L. participated in planning the trial. She actively participated in writing the protocol, the applications to the medicines agencies and ethics committees and helped writing the final manuscript. P.B. and the National Institute for Health and Care Research Cambridge Biomedical Research Centre, Core Biochemistry Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust analyzed the serum C-peptide samples. H.H. participated in the planning of the trial, tested the potential antiviral drugs, analyzed all virus data for the trial and assisted with preparing the final manuscript. J.L. participated in planning the trial, contributed to the C-peptide data with the statistical power calculation and contributed to writing the final manuscript. K.F.H. participated in trial planning and in writing the final manuscript. J.J. was the trial manager in Copenhagen and supervised the staff. He applied to the Danish ethics committee and the Danish medicines agency. He participated in the interpretation of the results and helped with preparing the final manuscript. All authors collected the data, contributed intellectually and critically reviewed the scientific content of the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work. L.K. and K.D.-J. are the guarantors of this work and, as such, had full access to all the data in the study, verified the data and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.